<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160679</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-NKR-SER-2010/1</org_study_id>
    <nct_id>NCT01160679</nct_id>
  </id_info>
  <brief_title>Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia</brief_title>
  <acronym>PLEASURE</acronym>
  <official_title>Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, multi-center, 12 weeks naturalistic NIS trial will be conducted in 25
      hospitals in naturalistic treatment setting. There will be no experimental component
      associated with this study and all observational activities have to be part of routine care
      visit: baseline (week 0), week 4 and week 12.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The change of total score of SHAPS</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of total score of SHAPS</measure>
    <time_frame>At 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Clinical Global Impression (CGI)-Severity score</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Clinical Global Impression (CGI)-Severity score</measure>
    <time_frame>At 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients having a score of 1 or 2 in CGI-I score</measure>
    <time_frame>At 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of significantly improved patients in SHAPS total score (more than 30%)</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change MADRS total score</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change MADRS total score</measure>
    <time_frame>At 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of significantly improved patients in SHAPS total score (more than 30%)</measure>
    <time_frame>At 12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">231</enrollment>
  <condition>Schizophrenia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Department of psychiatry of 25 hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented clinical diagnosis of schizophrenia meeting the Diagnostic and Statistical
             Manual of Mental Disorders,(DSM-IV-TR) criteria

          -  Patients who already take one atypical at inclusion it is started at least 1 week and
             up to 4 weeks before the inclusion

        Exclusion Criteria:

          -  Meeting the criteria for any other (than schizophrenia) DSM-IV Axis I

          -  Patients with antipsychotic combinations (more than two agents)

          -  Patients who are already on any mood stabilizers and antidepressant

          -  Known lack of response to clozapine or treatment with clozapine within 4 weeks prior
             to enrollment

          -  Patients who have been treated with antipsychotics in depot formulations for the last
             two months

          -  Previous enrollment or randomisation of treatment in the present NIS

          -  Patients who had participated in other clinical trials within 4 weeks prior to
             enrollment period

          -  Pregnant women or women who are breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Woo Han, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gongju-si</city>
        <state>Chungcheongnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuncheon</city>
        <state>Gangwon-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yongin-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyeongju-si</city>
        <state>Gyeongsangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changnyeong-gun</city>
        <state>Gyeongsangnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>August 17, 2011</last_update_submitted>
  <last_update_submitted_qc>August 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marketing Company Medical Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>anhedonic features in patients with schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

